Title
|
|
|
|
The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
E-52862 is a selective sigma R-1 antagonist currently undergoing phase II clinical trials for neuropathic pain and represents a potential first-in-class analgesic. Here, we investigated the effect of single and repeated administration of E-52862 on different pain-related behaviours in several neuropathic pain models in rats: mechanical allodynia in cephalic (trigeminal) neuropathic pain following chronic constriction injury of the infraorbital nerve (IoN), mechanical hyperalgesia in streptozotocin (STZ)-induced diabetic polyneuropathy, and cold allodynia in oxaliplatin (OX)-induced polyneuropathy. Mechanical hypersensitivity induced after IoN surgery or STZ administration was reduced by acute treatment with E-52862 and morphine, but not by pregabalin. In the OX model, single administration of E-52862 reversed the hypersensitivity to cold stimuli similarly to 100 mg/kg of gabapentin. Interestingly, repeated E-52862 administration twice daily over 7 days did not induce pharmacodynamic tolerance but an increased antinociceptive effect in all three models. Additionally, as shown in the STZ and OX models, repeated daily treatment with E-52862 attenuated baseline pain behaviours, which supports a sustained modifying effect on underlying pain-generating mechanisms. These preclinical findings support a role for sigma R-1 in neuropathic pain and extend the potential for the use of selective sigma R-1 antagonists (e.g., E-52862) to the chronic treatment of cephalic and extra-cephalic neuropathic pain. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
Scientific reports. - London, 2011, currens
| |
Publication
|
|
|
|
London
:
Nature Publishing Group
,
2016
| |
ISSN
|
|
|
|
2045-2322
| |
DOI
|
|
|
|
10.1038/SREP24591
| |
Volume/pages
|
|
|
|
6
(2016)
, 11 p.
| |
Article Reference
|
|
|
|
24591
| |
ISI
|
|
|
|
000374253000002
| |
Pubmed ID
|
|
|
|
27087602
| |
Medium
|
|
|
|
E-only publicatie
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (open access)
|
|
|
|
| |
|